Care Management Systems Executives Charged With $83 Million COVID-19 Testing Kickback Scheme

Executives associated with Care Management Systems were charged in a federal indictment with conspiracy to violate the Anti-Kickback Statute and healthcare fraud in connection with an alleged $83 million scheme involving COVID-19 testing and related diagnostic services billed to Medicare.DOCUMENTED The charges described a scheme in which the defendants paid kickbacks — framed as marketing fees, referral payments, or other business arrangements — to individuals and entities that directed Medicare beneficiaries toward the company's testing services, regardless of whether those beneficiaries had a genuine clinical need for the tests being ordered.

The Anti-Kickback Statute makes it illegal to offer or pay anything of value to induce referrals of business covered by federal health programs. The statute exists because kickback-driven referrals substitute financial incentives for clinical judgment, potentially resulting in patients receiving services they do not need while federal programs pay for services whose primary justification is the referral payment rather than the patient's healthcare needs.DOCUMENTED

The COVID-19 Testing Fraud Environment

COVID-19 testing during the pandemic period generated substantial Medicare and Medicaid reimbursement, creating financial incentives for fraud schemes that used testing as a billing vehicle.DOCUMENTED The government's commitment to covering COVID-19 testing broadly, combined with the legitimate public health urgency of widespread testing, created a high-volume environment in which fraudulent billing could be easier to obscure than in routine healthcare contexts where testing volumes and patterns are more predictable.

The Care Management Systems case exemplifies a pattern in which the kickback structure — paying third parties to generate referrals — was applied to the COVID-19 testing context in the same way similar schemes have historically operated around genetic testing, laboratory services, and durable medical equipment.REVIEWED The underlying mechanism is consistent across healthcare fraud categories: identify a service that generates strong Medicare reimbursement, build a referral network paid to direct beneficiaries toward that service, and bill the program for services whose primary purpose is generating the reimbursement rather than meeting the patient's clinical needs.

Anti-Kickback Statute: What It Prohibits

The Anti-Kickback Statute prohibits offering, paying, soliciting, or receiving any remuneration — including money, gifts, or other benefits — to induce or reward referrals of patients covered by Medicare, Medicaid, or other federal health programs.DOCUMENTED The prohibition applies both to the entity paying the kickback and to the entity receiving it — both sides of the transaction face criminal exposure if the payments are connected to referrals of federally covered patients.

The statute has a set of defined safe harbors — permissible payment arrangements that do not violate the law even though they involve money flowing between parties in a referral relationship. The safe harbors cover arrangements like bona fide employment relationships, group purchasing organization agreements, and certain personal service contracts.DOCUMENTED Arrangements designed primarily to generate referrals and then structured to fit within a safe harbor's technical requirements, rather than arising from genuine business needs the safe harbor was designed to accommodate, are not protected and may still be charged as violations.

The Kickback Structure in the Alleged Scheme

In the Care Management Systems case, the kickback payments were allegedly structured as marketing fees, consulting payments, or similar business arrangements that gave them an apparent commercial rationale.DOCUMENTED The actual function of these payments, according to the indictment, was to compensate the receiving parties for directing Medicare beneficiaries to the company's testing services. The volume of referrals generated through these arrangements, and the absence of a meaningful clinical filtering process between referral and test order, were among the indicators that investigators used to characterize the payments as kickbacks rather than permissible business arrangements.

Schemes in which tests are ordered at scale without genuine clinical evaluation of individual patient needs are identifiable through pattern analysis of billing data — high volumes of the same test ordered by the same provider or set of providers, across a patient population with no coherent clinical profile that would predict that need, are statistical indicators that trigger investigation in both the OIG and the FBI's healthcare fraud units.REVIEWED

Enforcement Context and Implications

The $83 million figure in the Care Management Systems indictment represents the alleged total value of false claims submitted to federal programs through the scheme — a number used in calculating potential criminal fines and restitution amounts if convictions follow.DOCUMENTED Healthcare fraud cases that generate claimed losses in the tens of millions of dollars carry substantial sentencing exposure for individual defendants, with guidelines recommending prison terms that reflect both the financial scale and the breach of trust involved in defrauding federal health programs.

The Care Management Systems case was one of multiple COVID-19 testing fraud prosecutions brought during the coordinated enforcement initiative that the DOJ conducted targeting pandemic-era healthcare fraud. The scope of the initiative reflected both the scale of fraudulent activity identified and the enforcement community's determination to pursue accountability across the range of fraud patterns that emerged during and after the public health emergency.

The Anti-Kickback Statute's Long Enforcement Tail

Healthcare fraud cases involving the Anti-Kickback Statute often have enforcement timelines that extend years beyond the events described in the charges, because the complexity of healthcare billing records and the breadth of the conspiracy's reach — across multiple entities, multiple referring sources, and potentially thousands of patient encounters — requires substantial investigative work before charges are filed. The $83 million in alleged false claims in the Care Management Systems case represents a figure that would be painstakingly documented through individual claim review, cross-referenced against legitimate clinical justification records and the financial flows between the testing company and its referral network. For companies operating in healthcare settings where referral arrangements are involved, this enforcement timeline means that practices that seemed to carry limited risk during the pandemic period may generate criminal exposure several years later, when the investigative resources that identified the pattern have worked through the full documentary record.

Have documents relevant to this story? Reach us through our tips channel.